Christopher Posner - 28 Nov 2022 Form 3 Insider Report for KEMPHARM, INC (ZVRA)

Reporting relationship: Director
Issuer ticker: ZVRA
Reported as of: 28 Nov 2022
Net transaction value: $0
SEC form: 3
Accepted by SEC: 30 Nov 2022, 15:40:23 UTC
Prior SEC filing: 18 Nov 2022
Next SEC filing: 03 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Christopher A. Posner

Key filing fact

Christopher Posner filed Form 3 for KEMPHARM, INC (ZVRA) on 30 Nov 2022.

Key facts

This page summarizes Christopher Posner's Form 3 filing for KEMPHARM, INC (ZVRA).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 30 Nov 2022, 15:40.

Change

Previous filing in this sequence was filed on 18 Nov 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZVRA holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 28 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,500
Exercise price: $4.67
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 33.33% of the total shares subject to the option vest in equal annual installments beginning on November 28, 2023 through November 28, 2025, provided that at the relevant vesting dates such optionee's directorial relationship has not been terminated as defined in and as determined under the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer. The option expires ten years after the date of grant.

SEC remarks

Exhibit List: Exhibit 24 - Power of Attorney.